Earlier Phase 2 studies showed that treatment with alemtuzumab reduced the accumulation of disability and the frequency of relapses in people with early relapsing-remitting MS, compared to
Rebif® (interferon-beta-1a-
rebif/index.aspx, interferon beta-1a, EMD Serono, Inc. and Pfizer, Inc.). (New England Journal of Medicine 2008 359;17:30-45)
Rebif is a registered trademark of EMD Serono, Inc. and Pfizer, Inc.
http://www.nationalmssociety.org/news/news-detail/index.aspx?